ConforMIS Adds Jobs with $1.4M Loan

Finance and development agency MassDevelopment has provided a $1,445,000 loan from the Emerging Technology Fund to Burlington’s ConforMIS, a privately held medical device company.

During FY2010, MassDevelopment financed or managed 238 projects in 104 communities across the state generating investment of nearly $1.4 billion in the Massachusetts economy.

ConforMIS will use loan proceeds to purchase multiple pieces of fabrication equipment and instruments used in its Massachusetts-based manufacturing operations.

ConforMIS uses computed tomography scans and proprietary computer aided design technology to create customised knee implant solutions for each patient. This customised approach also allows for a highly efficient just-in-time delivery model that takes full advantage of manufacturing innovations such as 3D printing, according to the company.

At the end of last year, the company moved to a larger facility to accommodate its growth and manufacturing expansion. With the recent 510(k) clearance from the U.S. Food and Drug Administration for the iTotal CR, the only patient-specific total knee implant cleared for sale in the US, the company expects to accelerate its rapid growth.

The development is to also result in new Medical Device Jobs.

“With this new technology, ConforMIS will be able to provide knee replacements to those who are underserved by current designs,” says MassDevelopment president and CEO Marty Jones.

Jones adds, “The Emerging Technology Fund helps companies that are starting or expanding manufacturing in Massachusetts, and this project is a triple play: boosting production, creating jobs, and serving the health needs of the Commonwealth.”

“The loan from MassDevelopment will further support the expansion of our supply chain and manufacturing presence, which is critical to our competitiveness within the orthopedics industry,” said Dr. Philipp Lang, MD, CEO of ConforMIS.

Lang adds, “Ultimately, the loan will help ConforMIS push the orthopedics industry toward a more efficient and more personalised approach to osteoarthritis treatment, and ultimately to enhance patients’ quality of life.”